Q-omics provides the consensus-scored GORASP2 profile across patient tissues and cancer cell-line models. GORASP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GORASP2 is differentially expressed in 18, with the highest sampling consensus in LUAD. Additionally, GORASP2 protein abundance shows 38,730 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, LUAD, and HNSC as cancer lineages where GORASP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GORASP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GORASP2 survival associations across molecular data types. GORASP2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GORASP2 RNA expression–survival associations across cancer types. High GORASP2 expression shows unfavorable associations in KIRP, ACC, CESC, LIHC and PAAD, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GORASP2 RNA expression.
This table summarizes GORASP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 13. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GORASP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GORASP2 shows higher tumor expression in LUAD, HNSC, COAD, KIRP, LIHC and STAD. The LUAD box plot shows higher GORASP2 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with GORASP2 in patient tissues and cancer cell lines. In patient samples, GORASP2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, GORASP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
